SCHEMBL6448185

SCHEMBL6448185

CC1(C(=O)O)CNc2ccccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.39
PDK2 Q15119 1/20 0.39
PDK4 Q16654 1/20 0.39
THRB P10828 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
AKR1C1 Q04828 1/20 0.35
NPSR1 Q6W5P4 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ADRB2 P07550 1/20 0.35
ATM Q13315 1/20 0.35
GAA P10253 2/20 0.34
LMNA P02545 2/20 0.34
MAPT P10636 1/20 0.34
BACE1 P56817 1/20 0.34
SIRT5 Q9NXA8 1/20 0.33
KDM1A O60341 1/20 0.33
NOTUM Q6P988 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29897781 1.00 BRD4 (0.39) BRD4PDK2PDK4THRBTDP1
SCHEMBL22864629 0.84 BRD4 (0.38) BRD4PDK2PDK4NPSR1KMT2A
SCHEMBL22864673 0.81 BRD4 (0.37) BRD4PDK2PDK4NPSR1MEN1
SCHEMBL29897761 0.81 KDM4E (0.43) BRD4PDK2PDK4MEN1KMT2A
SCHEMBL20506587 0.81 KDM4E (0.43) BRD4PDK2PDK4MEN1KMT2A
SCHEMBL31378040 0.81 BRD4 (0.37) BRD4PDK2PDK4NPSR1MEN1
SCHEMBL9364772 0.78 BRD4 (0.59) BRD4MEN1KMT2ASMN1; SMN2GAA
SCHEMBL30309711 0.77 CYP2C19 (0.42) BRD4PDK2PDK4NPSR1SMN1; SMN2
SCHEMBL19614159 0.75 MAPT (0.35) BRD4PDK2PDK4THRBTDP1
SCHEMBL13732518 0.75 BRD4 (0.40) BRD4PDK2PDK4THRBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612424-B2 HPK1 inhibitors and uses thereof REGOR PHARMACEUTICALS, INC. (US) 2026-04-28 US disclosed
US-20220389037-A1 HPK1 INHIBITORS AND USES THEREOF REGOR PHARMACEUTICALS, INC. 2022-12-08 US disclosed
EP-3377501-A1 FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS LifeArc (GB) 2018-09-26 EP disclosed
US-20050080084-A1 Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage PHARMACIA CORPORATION 2005-04-14 US disclosed
WO-2005018541-A2 COX-2 INHIBITOR AND SEROTONIN MODULATOR FOR TREATING CNS DAMAGE PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612424-B2 HPK1 inhibitors and uses thereof NEK11, NEK1, CSNK1A1 BRD4 1821/4885PDK2 372/4885PDK4 477/4885
US-20220389037-A1 HPK1 INHIBITORS AND USES THEREOF HIPK1, SIK1, PGK1 BRD4 2999/4885PDK2 127/4885PDK4 199/4885
US-20050080084-A1 Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage TPH2, TPH1, HTR2A BRD4 3817/4885PDK2 2665/4885PDK4 3871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.